2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1677

Serum Complement C3 Component As a Potential Disease Activity Marker in Psoriatic Arthritis
Abstract Number: 1678

JAK STAT Kinase Cascade Regulates the IL-23/IL-17 Cytokine Axis in Psoriatic Arthritis
Abstract Number: 1679

Predictors of Persistency with TNFi in Biologic-Experienced Versus Biologic-Naive Psa Patients Enrolled in the Corrona Registry
Abstract Number: 1680

Apremilast Monotherapy As the First Systemic Treatment in DMARD-Naive Patients with Active Psoriatic Arthritis: 3-Year Treatment Results
Abstract Number: 1681

Beneficial Effect of n-3 Polyunsaturated Fatty Acids on Inflammation and Analgesic Use in Psoriatic Arthritis – a Randomised, Double Blind, Placebo-Controlled Trial
Abstract Number: 1682

Tnfα Inhibitors Are Associated with Reduced Progression of Carotid Atherosclerotic Plaques By Ultrasound and an Improvement in Aortic Arch Vascular Inflammation By 18-FDG PET/CT in Psoriasis and Psoriatic Arthritis Patients – a Prospective Study from Two Cohorts
Abstract Number: 1683

Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis—Descriptive Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Abstract Number: 1684

Updated Results for Serious Infections in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Abstract Number: 1685

Updated Results for All-Cause Mortality and Malignancies in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Abstract Number: 1686

Association of Early Skin Improvement with ACR Responses Among Biologic DMARD-Naive Psoriatic Arthritic Patients Treated with Ixekizumab
Abstract Number: 1687

Effect of Concomitant Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) on the Efficacy and Safety of Ixekizumab in Biologic DMARD-Naive Patients with Active Psoriatic Arthritis
Abstract Number: 1688

Ixekizumab Provides Sustained Improvement up to 52 Weeks of Disease Activity As Assessed By Composite Measure Scores in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Abstract Number: 1689

Ixekizumab Provides Improvements through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Abstract Number: 1690

Efficacy and Safety of Apremilast and Switch from Etanercept in Patients with Moderate to Severe Psoriasis: 52-Week Results
Abstract Number: 1691

The Comparative Immunogenicity of Biologic Therapy and Its Clinical Relevance in Psoriatic Arthritis: A Systematic Review of the Literature

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].